(009) Testosterone Management in Women with Hypoactive Sexual Desire Disorder Who Have Reduced 5α-Reductase Activity: A Unique Population

Abstract Introduction According to the Global Consensus Position Statement on Use of Testosterone Therapy for Women, testosterone can significantly improve desire in menopausal women with hypoactive sexual disorder. Based safety and efficacy different formulations, recommended treatment is 1/10th a man’s dose, using government approved topical gel or solution, AndroFeme which use Australia. There are, however, subset without significant improvement this dose who experience higher doses testosterone. These have low lower tertile dihydrotestosterone blood test values despite their total being above normal range even upper tertile. The enzyme 5α-reductase converts more active form, dihydrotestosterone, that has affinity androgen receptor than activity varies individuals. It postulated there are HSDD reduced 5α- reductase therefore require from need formulation realize clinical benefit. This do not appear usual adverse side effects elevated (acne, thinning scalp hair, facial aggressive behavior), part because levels dihydrotestosterone. Objectives study examines products men. Methods retrospective chart review were provided menopause management at our clinic focusing whom solution did provide symptom relief. Options included increasing administration an alternative delivery system FDA (for men) including insertion one two 75 mg pellets (Testopel) weekly intramuscular injection cypionate (100 mg/ml – 0.1 ml 10 mg). Results A 11 (mean age 58 +/− 6 years) failed HSDD. Using pellet therapy, 1-2 implanted every 4-6 months, patients had excellent as well energy self-confidence; 4 response IM administration; 1 improved symptoms by tube/4 days. While these treatments resulted systemic outside 200 ng/dl), remained value 36 8 ng/dl; 30 80 ng/dl). In general, be expected experienced values. No patient complained consistent excess other mild hair. Conclusions some activity, result quality life negative physiologic Disclosure No.